NCT06360211View on ClinicalTrials.gov

A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 17, 2024

Primary Completion Date

June 28, 2024

Study Completion Date

June 28, 2024

Conditions
Advanced Non-small Cell Lung CancerEGFR MutationHER2 MutationHealthy Volunteers
Interventions
DRUG

BAY2927088

Oral administration

DRUG

Midazolam

Oral administration

Trial Locations (1)

21225

Parexel Baltimore - Early Phase Clinical Unit, Baltimore

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT06360211 - A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants | Biotech Hunter | Biotech Hunter